

Carbon Reduction Plan

Supplier name: Eurocept International B.V., trading name Lucane Pharma.

Publication date: 12/07/2024

Commitment to achieving Net Zero

Lucane Pharma is committed to achieving Net Zero emissions by 2050.

Baseline Emissions Footprint

Baseline Year: 1st February 2023 - 31st January 2024

The Lucane Pharma UK operation is a small part of Eurocept Pharmaceuticals Holding, the umbrella organization located and registered in the Netherlands and operating internationally. Lucane Pharma does not own or lease any UK assets including facilities and fleet. All employees of Lucane Pharma UK are home-based. Therefore, the Scope 1 and 2 emissions are not applicable (N/A) under the TOTAL (tCO₂e).

This is the first year of reporting, so the Baseline year reporting and the Current emissions reporting are identical.

Baseline year emissions:

EMISSIONS	TOTAL (tCO ₂ e)														
Scope 1	N/A														
Scope 2	N/A														
Scope 3 (Included Sources)	<table border="1"> <thead> <tr> <th>Category</th> <th>Emissions (tCO₂e)</th> </tr> </thead> <tbody> <tr> <td>Upstream transportation and distribution</td> <td>0.34</td> </tr> <tr> <td>Waste generated in operations</td> <td>N/A</td> </tr> <tr> <td>Business travel</td> <td>5.33</td> </tr> <tr> <td>Employee commuting</td> <td>0.51</td> </tr> <tr> <td>Downstream transportation and distribution</td> <td>0.08</td> </tr> <tr> <td>Total</td> <td>6.26</td> </tr> </tbody> </table>	Category	Emissions (tCO ₂ e)	Upstream transportation and distribution	0.34	Waste generated in operations	N/A	Business travel	5.33	Employee commuting	0.51	Downstream transportation and distribution	0.08	Total	6.26
	Category	Emissions (tCO ₂ e)													
	Upstream transportation and distribution	0.34													
	Waste generated in operations	N/A													
	Business travel	5.33													
	Employee commuting	0.51													
	Downstream transportation and distribution	0.08													
Total	6.26														
Total Emissions	6.26														

AN

Current Emissions Reporting

Reporting Year: 1st February 2023 - 31st January 2024															
EMISSIONS	TOTAL (tCO ₂ e)														
Scope 1	N/A														
Scope 2	N/A														
Scope 3 (Included Sources)	<table border="1"> <thead> <tr> <th>Category</th> <th>Emissions (tCO₂e)</th> </tr> </thead> <tbody> <tr> <td>Upstream transportation and distribution</td> <td>0.34</td> </tr> <tr> <td>Waste generated in operations</td> <td>N/A</td> </tr> <tr> <td>Business travel</td> <td>5.33</td> </tr> <tr> <td>Employee commuting</td> <td>0.51</td> </tr> <tr> <td>Downstream transportation and distribution</td> <td>0.08</td> </tr> <tr> <td>Total</td> <td>6.26</td> </tr> </tbody> </table>	Category	Emissions (tCO ₂ e)	Upstream transportation and distribution	0.34	Waste generated in operations	N/A	Business travel	5.33	Employee commuting	0.51	Downstream transportation and distribution	0.08	Total	6.26
	Category	Emissions (tCO ₂ e)													
	Upstream transportation and distribution	0.34													
	Waste generated in operations	N/A													
	Business travel	5.33													
	Employee commuting	0.51													
	Downstream transportation and distribution	0.08													
Total	6.26														
Total Emissions	6.26														

Carbon Intensity

To convert absolute emissions to an emissions intensity metric, Lucane Pharma have calculated emissions per relevant unit of measure. The metric(s) selected to normalise emissions are Employees (FTE) and Product Shipped (Tonnes).

The intensity ratio(s) as well as the business metric(s) are detailed below. The intensity ratio is calculated based on total emissions (location based).

Business Metric	Baseline Year	Reporting Year
	01/02/2023 - 01/02/2024	01/02/2023 - 01/02/2024
Employees (FTE)	1.5	1.5
Product Shipped (Tonnes)	0.52	0.52

Carbon Emissions per Business Metric	Baseline Year	Reporting Year
	01/02/2023 - 01/02/2024	01/02/2023 - 01/02/2024
Emission per Employees (tCO ₂ e/FTE)	4.16	4.16
Emission per Product Shipped (tCO ₂ e/Tonnes)	12.06	12.06


Emissions reduction targets

In order to continue our progress towards achieving Net Zero emissions, we have adopted the following carbon reduction targets: Net Zero emissions by 2050 with a 20% reduction to be achieved by 2029.

This is Lucane Pharma's first carbon footprint, therefore there are no previous emission reduction commitments.

We project that carbon emissions will decrease over the next five years to 5tCO₂e by 2029. This is a reduction of 20%.

Progress against these targets can be seen in the graph below:



Carbon Reduction Projects

Completed Carbon Reduction Initiatives:

This is the first year of reporting and therefore no environmental management measures have been formally completed / reported at this point of time.

In the future Lucane Pharma is committed to implement further measures in the UK such as:

- Encourage business traveling by train and reduce a number of short haul flights where possible.
- Decrease the fuel emissions through encouraging the use of electric or hybrid vehicles.

In the future, Eurocept International B.V. / Lucane Pharma's headquarter in Ankeveen, The Netherlands aims to continue to reduce their carbon emission through implementation of relevant processes and procedures across the whole company (Eurocept Pharmaceuticals Holding).

For example, in 2023 Eurocept International Holding went through RfP tender of a new transport provider / logistics partner. One of the selection criteria was minimalization of carbon footprint.

As a result of this tender, Eurocept Pharmaceuticals Holding, the transport provider was selected with the strong sustainability vision and carbon reduction objectives. Besides that, this logistics provider consolidates shipments, resulting in less number of individual shipments. Eurocept Pharmaceuticals Holding has commenced working with this logistics partner as per December 2023.

Future company-wide carbon footprint reduction initiatives, include, but not limited by the following areas:

- Start a sustainability task force to assess current operations and develop solutions to reduce carbon emissions - both within the organisation and by working with external partners.
- Demonstrate right “Tone at the top” around sustainability– the board members of Eurocept Pharmaceuticals Holding’s Pharma Leadership team (PLT) continuously “walk the talk” around different sustainability measures and lead by example in all related aspects to achieve Net Zero emission commitment.
- Upskill and raise awareness for all company employees to engage them to change behaviours on the daily basis – in order to drive and enforce the Net Zero emissions vision of Eurocept Pharmaceuticals Holding. Upgrade the company’s car lease policy, to further transition to electric and hybrid cars (for company car lease-eligible employees) and encourage the use of bikes and e-bikes (for employees that live inside of a radius of 15 km of the office/ warehouse). Stimulate all other employees (not eligible for a company car lease) to follow the same principles.
- Reduce the use of electricity combined with introducing of the solar panels on the roof areas, where technically feasible, and in line with local rules and regulations.
- Introduce a more sustainable way of traveling, consistently. Where possible, business travel will take place using trains instead of air travel. If multiple individuals have to go to the same external appointment, carpooling will be further encouraged, to contribute to the reduction of the emissions.
- Optimize the company’s waste management: assess Eurocept Pharmaceuticals Holding’s “waste partner”, make a plan to lower the amount of waste and increase re-utilization of waste/ plastics.
- Where feasible, utilize European contract manufacturing organizations (CMOs) to produce the medicinal products in Europe.
- Continue to utilize Eurocept Pharmaceuticals Holding’s local production facility in the Netherlands to minimize waste (driven by minimalization of transportation, better usage of secondary packaging materials etc.).
- Keep taking initiatives with relevant authorities to facilitate derogations (post approvals of authorities) – to secure product availability to patients and optimize product utilization (minimizing risk of waste).

Declaration and Sign Off


This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:



A. Novikova, Finance & Operations Director

Date: *01/08/2024*

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>